Home > Insider Trading > Filing (0001213900-20-045804)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1218683	Wize Pharma Inc.	WIZP	Pharmaceutical Preparations (2834)	880445167

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1723667	Brian Jonathan Rubini	C/O Wize Pharma, Inc. 24 Hanagar Street Hod Hasharon L3 4527708		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-29	4,074,074	$0.00	6,529,813	No	4	X	Direct
Common Stock	Disposition	2020-12-29	33,951	$0.00	6,495,862	No	4	S	Direct
Common Stock	Acquisiton	2020-12-29	350,000	$0.00	6,845,862	No	4	X	Direct
Common Stock	Disposition	2020-12-29	2,692	$0.00	6,843,170	No	4	S	Direct
Common Stock	Acquisiton	2020-12-29	259,037	$0.00	7,102,207	No	4	X	Direct
Common Stock	Disposition	2020-12-29	2,159	$0.00	7,100,048	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	X	Direct
No	4	S	Direct
No	4	X	Direct
No	4	S	Direct
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (right to buy)	Disposition	2020-12-29	4,074,074	$0.00	4,074,074	$0.27
Common Stock	Warrant (right to buy)	Disposition	2020-12-29	350,000	$0.00	350,000	$0.16
Common Stock	Warrant (right to buy)	Disposition	2020-12-29	259,037	$0.00	259,037	$1.97

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	2024-12-19	No	4	X	Direct
2019-04-21	2023-10-23	No	4	X	Direct
2017-11-16	2020-12-31	No	4	X	Direct

Footnotes

On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.
On December 29, 2020 the reporting person exercised a warrant to purchase 4,074,074 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 33,951 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,040,123 shares.
On December 29, 2020 the reporting person exercised a warrant to purchase 350,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,692 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,308 shares.
On December 29, 2020 the reporting person exercised a warrant to purchase 259,037 shares of the registrant's common stock for $1.97 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,159 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 256,878 shares.
Exercisable five days following the public announcement of positive clinical data results for LO2A.
The expiration date was extended from 11/16/2029 to 12/31/2020.